In this open-label trial, a higher proportion of asymptomatic follicular lymphoma patients assigned to rituximab required no further treatment at nearly 15 years compared with those assigned to ...

ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced the launch of ResQ215B, a Phase 2 ...

This was an open-label, single-arm, single-center phase II study enrolling 40 patients. During the first week of the study, patients received two infusions of rituximab 375 mg/m 2 administered 4 days ...

The study builds on data from an early-stage study which evaluated CD19 CAR-NK cell therapy in combination with the Rituximab ...

A groundbreaking phase 2 trial explores a novel, chemotherapy-free immunotherapy for relapsed indolent B-cell lymphomas, aiming to enhance patient outcomes.

The watchful waiting approach defers chemotherapy, on average, for about 2.5 years. This time was significantly increased in the new study in patients on rituximab — the median time to initiation of ...

Follicular lymphoma -- typically a slow-growing or indolent form of non-Hodgkin lymphoma that arises from B lymphocytes -- accounts for 20% to 30% of all non-Hodgkin lymphoma cases. The indolent ...

December 12, 2011 (San Diego, California) — For more than a decade now, rituximab (Rituxan, Genentech) has reigned supreme as the only drug of its kind — a monoclonal antibody specifically targeting ...

LONDON (Reuters) - Lymphoma patients who continue regular infusions of Genentech Inc and Biogen Idec's Rituxan after chemotherapy may live longer than patients who stop, Israeli researchers said on ...